MX2012000016A - Conjugados de peptidos multimericos y sus usos. - Google Patents

Conjugados de peptidos multimericos y sus usos.

Info

Publication number
MX2012000016A
MX2012000016A MX2012000016A MX2012000016A MX2012000016A MX 2012000016 A MX2012000016 A MX 2012000016A MX 2012000016 A MX2012000016 A MX 2012000016A MX 2012000016 A MX2012000016 A MX 2012000016A MX 2012000016 A MX2012000016 A MX 2012000016A
Authority
MX
Mexico
Prior art keywords
multimeric
agents
peptide conjugates
multimeric peptide
bbb
Prior art date
Application number
MX2012000016A
Other languages
English (en)
Inventor
Michel Demeule
Christian Che
Carine Thiot
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of MX2012000016A publication Critical patent/MX2012000016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formas multiméricas (v.gr., dímericas, triméricas) de vectores de péptidos que son capaces de cruzar la barrera hematoencefalica (BBB) o ingresar de manera eficiente a tipos de células particulares. Estos vectores de péptidos multiméricos cuando se conjugan con agentes (v. gr., agentes terapéuticos) son capaces de transportar agentes a través de la BBB o hacia tipos de células particulares. Estos compuestos por lo tanto son particularmente útiles en el tratamiento de trastornos neurológicos.
MX2012000016A 2009-07-02 2010-06-30 Conjugados de peptidos multimericos y sus usos. MX2012000016A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22278509P 2009-07-02 2009-07-02
US25202409P 2009-10-15 2009-10-15
PCT/CA2010/001014 WO2011000095A1 (en) 2009-07-02 2010-06-30 Multimeric peptide conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2012000016A true MX2012000016A (es) 2012-03-26

Family

ID=43410407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000016A MX2012000016A (es) 2009-07-02 2010-06-30 Conjugados de peptidos multimericos y sus usos.

Country Status (12)

Country Link
US (1) US9161988B2 (es)
EP (1) EP2448965A4 (es)
JP (1) JP5932642B2 (es)
CN (1) CN102596993A (es)
AU (1) AU2010268726A1 (es)
BR (1) BRPI1015918A2 (es)
CA (1) CA2766537A1 (es)
IN (1) IN2012DN00248A (es)
MX (1) MX2012000016A (es)
RU (1) RU2012103240A (es)
WO (1) WO2011000095A1 (es)
ZA (1) ZA201109324B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
ES2424242T3 (es) 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX2011004017A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de agonistas glp-1 y usos de los mismos.
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
JP2012512185A (ja) 2008-12-17 2012-05-31 アンジオケム インコーポレーテッド 膜１型マトリックス金属タンパク質阻害剤およびその使用
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (es) 2009-07-02 2015-05-01 Angiochem Inc
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MA38276B1 (fr) 2012-12-21 2018-03-30 Sanofi Sa Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
EP2968153B1 (en) * 2013-03-12 2018-05-02 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
EP3004140A4 (en) * 2013-06-06 2017-01-25 Angiochem Inc. Targeted enzyme compounds and uses thereof
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015124540A1 (en) * 2014-02-19 2015-08-27 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
BR112017024206A2 (pt) * 2015-05-11 2018-07-17 Janssen Vaccines & Prevention Bv compostos peptidomiméticos neutralizadores do vírus da gripe
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
AR105284A1 (es) * 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
BR112018010535A2 (pt) 2015-11-24 2018-11-13 Transfert Plus Sec compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
PL3393496T3 (pl) 2015-12-23 2024-04-22 The Johns Hopkins University Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
CN105481975A (zh) * 2015-12-31 2016-04-13 南京工业大学 治疗II型糖尿病的α-螺旋多肽及其制备方法与应用
CN110582302A (zh) * 2016-12-14 2019-12-17 利甘达尔股份有限公司 用于核酸和/或蛋白有效负载递送的组合物和方法
WO2018118015A1 (en) 2016-12-19 2018-06-28 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
WO2020036987A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies
WO2023147053A2 (en) * 2022-01-28 2023-08-03 Sigilon Therapeutics, Inc. Therapies for mucopolysaccharidosis type 6
WO2023150552A1 (en) 2022-02-04 2023-08-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of neurological disorders
CN115353551B (zh) * 2022-06-27 2024-01-26 上海理工大学 一种燕麦源促glp-1分泌寡肽及其制备方法和应用

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
AU599373B2 (en) 1986-03-13 1990-07-19 Biotechnology Australia Proprietary Limited Method of assay of inhibin
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5807980A (en) 1992-07-13 1998-09-15 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor VIIa-tissue factor complex
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
JPH06228199A (ja) * 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
WO1994019692A1 (en) 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
WO1996035788A2 (en) 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
EP0966303A2 (en) 1996-05-01 1999-12-29 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE69838544T2 (de) 1997-03-04 2008-07-24 Savient Pharmaceuticals, Inc. Isolierung von gewebespezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
BR9809138A (pt) 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2362937C (en) 1999-02-24 2011-03-22 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
DE60006100T2 (de) * 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
JP2003509488A (ja) 1999-09-24 2003-03-11 ジェネンテック・インコーポレーテッド チロシン誘導体
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
CA2355334A1 (en) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
WO2002043765A2 (en) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
CZ308214B6 (cs) 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
IL157993A0 (en) 2001-03-23 2004-03-28 Napro Biotherapeutics Inc Molecular conjugates for use in cancer treatment and methods for the preparation thereof
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
JP2005517024A (ja) 2002-02-07 2005-06-09 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 生物学的障壁を横切る透過を促進し得るアミノ酸配列
EP1495045B1 (en) 2002-03-29 2009-09-02 Creagene, Inc. Cytoplasmic transduction peptides and uses thereof
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
AU2003237314B2 (en) 2002-05-29 2010-03-04 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
WO2004003145A2 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
US9221867B2 (en) * 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US20040162284A1 (en) 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
ATE546151T1 (de) 2003-04-08 2012-03-15 Biotempt Bv Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung
EP2664672A1 (en) 2003-04-17 2013-11-20 Alnylam Pharmaceuticals Inc. Modified iRNA agents
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004263458B2 (en) 2003-08-08 2010-06-24 Actgen, Inc. Polypeptides having brain-localizing activity and uses thereof
US20070275871A1 (en) 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
NZ553224A (en) 2004-07-26 2009-05-31 Asterion Ltd Linkers
EP1799826B1 (en) 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP2360258B1 (en) 2005-02-18 2014-10-08 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
US20090246211A1 (en) 2005-05-12 2009-10-01 Henri John T Molecular constructs suitable for targeted conjugates
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
ES2424242T3 (es) 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois TRANSPORT AGENTS USEFUL FOR CROSSING THE HEMATO-ENCEPHALIC BARRIER AND FOR PENETRATING IN CANCER CELLS OF THE BRAIN, METHODS OF USING THE SAME
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
JP2009507852A (ja) 2005-09-08 2009-02-26 エムディーアールエヌエー，インコーポレイテッド リボ核酸の細胞への送達用医薬組成物
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
EP1996220B2 (en) * 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
WO2007053696A2 (en) 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US8290433B2 (en) 2007-11-14 2012-10-16 Blaze Mobile, Inc. Method and system for securing transactions made through a mobile communication device
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
US7477504B1 (en) 2006-03-13 2009-01-13 C.P.D. Technologies, Inc. Versatile stun glove
SI2177536T1 (sl) * 2006-03-30 2014-09-30 Glaxo Group Limited Protitelesa proti amiloidnemu peptidu beta
EP2043696B1 (en) 2006-07-13 2015-02-25 Burnham Institute for Medical Research Methods and compositions for targeting gc1qr/p32
AU2007278994B2 (en) 2006-07-24 2013-08-15 Biorexis Pharmaceutical Corporation Exendin fusion proteins
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
WO2008069876A2 (en) 2006-10-27 2008-06-12 University Of Kentucky Research Foundation Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
MX2009010148A (es) 2007-03-21 2009-12-01 Raptor Pharmaceutical Inc Peptidos ciclicos de proteinas receptor-asociadas (rap).
CA2688344C (en) * 2007-05-29 2019-09-03 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en) 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
NZ584048A (en) 2007-10-02 2012-08-31 Marina Biotech Inc Lipopeptides for delivery of nucleic acids
WO2009070597A2 (en) * 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
RU2010129761A (ru) * 2007-12-20 2012-01-27 Ангиочем Инк. (Ca) Конъюгаты полипептидов с нуклеиновыми кислотами и их применение
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2250278B1 (en) 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
CA2721019C (en) 2008-04-18 2015-09-15 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2010006239A2 (en) 2008-07-10 2010-01-14 The Board Of Trustees Of The University Of Illinois Regulation of apoptosis by neural specific splice variants of ig20
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
MX2011004017A (es) * 2008-10-15 2011-06-24 Angiochem Inc Conjugados de agonistas glp-1 y usos de los mismos.
JP2012510797A (ja) 2008-12-05 2012-05-17 アンジオケム インコーポレーテッド レプチンおよびレプチン類似体コンジュゲートならびにそれらの使用
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CA2745499A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
JP2012512185A (ja) 2008-12-17 2012-05-31 アンジオケム インコーポレーテッド 膜１型マトリックス金属タンパク質阻害剤およびその使用
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20100284921A1 (en) 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
CN102497870A (zh) 2009-06-03 2012-06-13 戴瑟纳制药公司 肽-dicer底物试剂及其特异性抑制基因表达的方法
MX2011013258A (es) 2009-06-11 2012-02-28 Angiochem Inc Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central.
IN2012DN00248A (es) 2009-07-02 2015-05-01 Angiochem Inc
WO2011008823A2 (en) 2009-07-14 2011-01-20 Mayo Foundation For Medical Education And Research Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
EP2486061A4 (en) 2009-10-06 2013-08-28 Angiochem Inc COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
EP4201402A1 (en) 2010-03-08 2023-06-28 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
US9102697B2 (en) 2010-03-22 2015-08-11 President And Fellows Of Harvard College Trioxacarcins and uses thereof
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
CA2796215C (en) 2010-04-14 2021-05-18 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
WO2011153642A1 (en) 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
CN103080125A (zh) 2010-07-02 2013-05-01 安吉奥开米公司 用于治疗性结合物的短且含d氨基酸的多肽及其使用
US8218280B2 (en) 2010-07-08 2012-07-10 Schneider Electric USA, Inc. Secondary thermal sensor for primary conductors
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
WO2012037687A1 (en) 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
RU2018102375A (ru) 2010-11-18 2019-02-21 Зе Дженерал Хоспитал Корпорейшен Новые композиции и применения антигипертензивных средств для терапии рака
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药***及其制备方法
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药***
EP2680820B1 (en) 2011-03-01 2022-11-02 2-BBB Medicines B.V. Advanced active liposomal loading of poorly water-soluble substances
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2012138694A2 (en) 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
RU2013154422A (ru) 2011-05-09 2015-06-20 Институт Кимик Де Саррия Полимерные наночастицы, предназначенные для доставки лекарственных средств
WO2013004716A1 (en) 2011-07-04 2013-01-10 Universität Basel Peptide beads
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
EA027970B1 (ru) 2011-08-11 2017-09-29 ИНТЕЛЛАЙКИН, ЭлЭлСи Полиморфы ингибитора киназы
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013056096A1 (en) 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
NZ747501A (en) 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
JP6078076B2 (ja) 2011-11-11 2017-02-08 インテリカイン， エルエルシー キナーゼ阻害剤多形体
AU2012344700A1 (en) 2011-12-01 2014-06-19 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
WO2013078564A2 (en) 2011-12-01 2013-06-06 Angiochem Inc. Targeted lysosomal enzyme compounds
US9844598B2 (en) 2011-12-13 2017-12-19 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
BR112014014599A2 (pt) 2011-12-16 2017-06-13 Massachusetts Inst Technology polímeros de alfa-aminoamidina e uso dos mesmos
WO2013120107A1 (en) 2012-02-09 2013-08-15 University Of Rochester Methods and compositions for treating a subject to inhibit hearing loss
EP2819686A4 (en) 2012-03-02 2016-05-25 Icahn School Med Mount Sinai PROTHYMOSIN ALPHA VARIANTS AND METHODS OF USE
SI2833905T1 (en) 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and tumane-directed taxane
ES2905359T3 (es) 2012-04-26 2022-04-08 Univ Yale Moléculas de suministro de fármacos citotóxicos dirigidas al VIH (CDM-H), actividad citotóxica contra el virus de la inmunodeficiencia humana y métodos de uso
WO2013185235A1 (en) 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduronidase compounds

Also Published As

Publication number Publication date
EP2448965A4 (en) 2015-02-11
WO2011000095A1 (en) 2011-01-06
IN2012DN00248A (es) 2015-05-01
RU2012103240A (ru) 2013-08-10
AU2010268726A1 (en) 2012-01-19
BRPI1015918A2 (pt) 2019-09-24
JP5932642B2 (ja) 2016-06-08
JP2012531467A (ja) 2012-12-10
EP2448965A1 (en) 2012-05-09
CN102596993A (zh) 2012-07-18
US20120141416A1 (en) 2012-06-07
US9161988B2 (en) 2015-10-20
ZA201109324B (en) 2013-02-27
CA2766537A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
MX2012000016A (es) Conjugados de peptidos multimericos y sus usos.
MX2011005964A (es) Conjugados terapeuticos de peptidos y sus usos.
MX2011005963A (es) Conjugados de neurotensina o analogos de neurotensina y sus usos.
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
NZ711373A (en) Fragments of p97 and uses thereof
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
WO2009012176A3 (en) Methods and compositions for treating brain diseases
ZA200706917B (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
EP2307038A4 (en) THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
MX2009002547A (es) Composiciones terapeuticas de peptido de fusion.
EA201491346A1 (ru) Усиление транспорта терапевтических молекул через гематоэнцефалический барьер
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
MX357801B (es) Agentes dirigidos a gadd45beta.
MX2011005965A (es) Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
IN2012DN00908A (es)
HK1142828A1 (en) Hydrolysable polymeric fmoc-linker
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
CR11692A (es) USO DE VARIANTES DE IGF-I PEGiladas PARA EL TRATAMIENTO DE TRASTORNOS NEUROMUSCULARES
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης